BARR RECEIVES APPROVAL FOR CLONAZEPAM TABLETS

Barr Laboratories has received final approval from the FDA for its application to manufacture and market Clonazepam Orally Disintegrating Tablets in 0.125-mg, 0.25-mg, 0.5-mg, 1-mg and 2-mg dosage strengths.

Barr's product is the generic equivalent of Hoffman-La Roche's Klonopin Wafers. Clonazepam is intended to treat Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures, and panic disorder, with or without agoraphobia, as defined in DSM-IV. Klonopin Wafers had total annual sales of approximately $18 million, based on IMS sales data for the twelve months ended June 2005. Barr said it intends to launch its product immediately.